Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.50 |
| ▸ | HTR2C | P28335 | 4/20 | 0.50 |
| ▸ | HTR2B | P41595 | 4/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | DRD4 | P21917 | 2/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11453737 | 0.83 | KDM4E (0.62) | HTR2AHTR2CHTR2BALDH1A1KDM4E | |
| SCHEMBL4406266 | 0.83 | GFER (0.42) | HTR2AHTR2CHTR2BGFERALDH1A1 | |
| SCHEMBL10977219 | 0.81 | ALDH1A1 (0.55) | HTR2AHTR2CHTR2BGFERALDH1A1 | |
| SCHEMBL10974938 | 0.81 | ALDH1A1 (0.55) | HTR2AHTR2CHTR2BGFERALDH1A1 | |
| SCHEMBL10974936 | 0.81 | ALDH1A1 (0.55) | HTR2AHTR2CHTR2BGFERALDH1A1 | |
| SCHEMBL5121758 | 0.78 | ALDH1A1 (0.68) | HTR2AHTR2CHTR2BALDH1A1KDM4E | |
| SCHEMBL7270310 | 0.78 | ALDH1A1 (0.68) | HTR2AHTR2CHTR2BALDH1A1KDM4E | |
| SCHEMBL7709727 | 0.78 | ALDH1A1 (0.68) | HTR2AHTR2CHTR2BALDH1A1KDM4E | |
| SCHEMBL11377237 | 0.78 | HTR2A (0.57) | HTR2AHTR2CHTR2BALDH1A1KDM4E | |
| SCHEMBL5710904 | 0.77 | ALDH1A1 (0.62) | HTR2AHTR2CHTR2BALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318412-A1 | Tricyclic heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-24 | — | — | US | claimed |
| US-20090318412-A1 | Tricyclic heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318412-A1 | Tricyclic heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318412-A1 | Tricyclic heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-24 | — | — | US | disclosed |
| US-7317005-B2 | Tricyclic benzodiazepines as vasopressin receptor antagonists | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| US-7317005-B2 | Tricyclic benzodiazepines as vasopressin receptor antagonists | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318412-A1 | Tricyclic heterocyclic compound and use thereof | HTR2C, HTR2A, HTR5A | HTR2A 2/4885HTR2C 1/4885HTR2B 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.